CStone Pharmaceuticals (HKG:2616)
8.33
+1.43 (20.72%)
At close: Mar 27, 2026
CStone Pharmaceuticals Revenue
In the year 2025, CStone Pharmaceuticals had annual revenue of 269.58M CNY, down -33.80%. CStone Pharmaceuticals had revenue of 49.45M in the half year ending June 30, 2025, a decrease of -81.09%.
Revenue
269.58M CNY
Revenue Growth
-33.80%
P/S Ratio
40.88
Revenue / Employee
2.06M CNY
Employees
131
Market Cap
12.27B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 269.58M | -137.62M | -33.80% |
| Dec 31, 2024 | 407.21M | -56.64M | -12.21% |
| Dec 31, 2023 | 463.84M | -17.52M | -3.64% |
| Dec 31, 2022 | 481.36M | 237.65M | 97.51% |
| Dec 31, 2021 | 243.72M | -795.11M | -76.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zai Lab | 3.58B |
| Shanghai Haohai Biological Technology | 2.75B |
| Everest Medicines | 1.90B |
| Lepu Biopharma | 1.04B |
| HBM Holdings | 908.35M |
| Abbisko Cayman | 681.17M |
| Alphamab Oncology | 630.11M |
| Ascentage Pharma Group International | 428.02M |
CStone Pharmaceuticals News
- 1 day ago - CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0 - PRNewsWire
- 1 day ago - CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) - PRNewsWire
- 4 weeks ago - CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC - PRNewsWire